Drug Search Results
Using advanced filters...
Advanced Search [+]

SHR-1139

Alternative Names: SHR-1139, SHR 1139, SHR1139
Latest Update: 2025-03-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: Subcutaneous,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Guangdong Hengrui Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SHR-1139

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SHR-1139-201

P2

Not yet recruiting

Psoriasis

2025-11-01

Recent News Events

Date

Type

Title